Patents by Inventor Atsushi Kumanogoh
Atsushi Kumanogoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357390Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.Type: ApplicationFiled: July 21, 2023Publication date: November 9, 2023Applicant: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama, Atsushi Kumanogoh
-
Patent number: 11576969Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.Type: GrantFiled: May 8, 2020Date of Patent: February 14, 2023Assignees: Osaka University, Chugai Seiyaku Kabushiki KaishaInventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
-
Publication number: 20220064287Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.Type: ApplicationFiled: November 16, 2021Publication date: March 3, 2022Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH
-
Publication number: 20220041735Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: March 22, 2021Publication date: February 10, 2022Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Patent number: 10988540Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: GrantFiled: June 18, 2020Date of Patent: April 27, 2021Assignee: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama, Atsushi Kumanogoh, Junichi Takagi
-
Publication number: 20210113594Abstract: The present invention provides a less expensive immunotherapy drug for tumor. Tumor immunity can be activated by at least one member selected from the group consisting of tetracycline-based compounds and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 13, 2019Publication date: April 22, 2021Inventors: Kota IWAHORI, Hisashi WADA, Yuki NOGUCHI, Atsushi KUMANOGOH
-
Publication number: 20210003571Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.Type: ApplicationFiled: August 28, 2020Publication date: January 7, 2021Applicant: OSAKA UNIVERSITYInventor: Atsushi KUMANOGOH
-
Publication number: 20200385474Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: June 18, 2020Publication date: December 10, 2020Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Patent number: 10794907Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.Type: GrantFiled: April 22, 2014Date of Patent: October 6, 2020Assignee: OSAKA UNIVERSITYInventor: Atsushi Kumanogoh
-
Publication number: 20200283533Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: March 4, 2020Publication date: September 10, 2020Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Publication number: 20200276302Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 8, 2020Publication date: September 3, 2020Inventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
-
Publication number: 20200270686Abstract: The principal purpose of the present invention is to provide a biomarker that makes it possible to conveniently and accurately assess corneal or conjunctival disease, and can use lacrimal fluid as the sample thereof. In addition, a main object of the present invention is to provide a biomarker that makes it possible to conveniently and accurately evaluate central serous chorioretinopathy. The present invention also provides a diagnostic kit containing a reagent capable of detecting the biomarker, and a diagnosis method that uses the biomarker. It is possible to use mitochondrial DNA included in lacrimal fluid as the biomarker for corneal or conjunctival disease.Type: ApplicationFiled: March 28, 2017Publication date: August 27, 2020Inventors: Kohji Nishida, Atsushi Kumanogoh, Noriyasu Hashida
-
Patent number: 10688178Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 2016Date of Patent: June 23, 2020Assignees: Osaka University, Chugai Seiyaku Kabushiki KaishaInventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
-
Patent number: 10654931Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: GrantFiled: August 2, 2016Date of Patent: May 19, 2020Assignee: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama, Atsushi Kumanogoh, Junichi Takagi
-
Publication number: 20190119747Abstract: The principal purpose of the present invention is to provide a novel stress biomarker that makes it possible to conveniently and accurately assess a state of stress. In addition, the present invention provides a diagnosis kit containing a reagent capable of detecting said biomarker, and a diagnosis method that uses said biomarker. It is possible to use mitochondrial DNA included in a biological fluid as the stress biomarker.Type: ApplicationFiled: March 28, 2017Publication date: April 25, 2019Inventors: Kohji Nishida, Atsushi Kumanogoh, Noriyasu Hashida
-
Publication number: 20180230212Abstract: Provided is an antibody effective in the treatment of tumors and the like. An antibody that includes an N-type glycosylation site of human CD98hc and recognizes an epitope exposed by inhibition of N-type glycosylation modification.Type: ApplicationFiled: August 9, 2016Publication date: August 16, 2018Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH
-
Publication number: 20180230216Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin ?7.Type: ApplicationFiled: August 2, 2016Publication date: August 16, 2018Applicant: OSAKA UNIVERSITYInventors: Naoki HOSEN, Haruo SUGIYAMA, Atsushi KUMANOGOH, Junichi TAKAGI
-
Publication number: 20180193451Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 30, 2016Publication date: July 12, 2018Applicants: OSAKA UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Atsushi KUMANOGOH, Ryusuke OMIYA, Hiroyuki TSUNODA, Takeshi BABA, Sachiyo SUZUKI, Yuri TERANISHI
-
Publication number: 20140349311Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.Type: ApplicationFiled: April 22, 2014Publication date: November 27, 2014Applicant: OSAKA UNIVERSITYInventor: Atsushi KUMANOGOH
-
Publication number: 20120322085Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.Type: ApplicationFiled: November 5, 2010Publication date: December 20, 2012Applicant: Osaka UniversityInventor: Atsushi Kumanogoh